LENSAR Inc. ( LNSR ) shares are down during Tuesday’s premarket session following the termination of a merger agreement with Alcon AG ( ALC ) .

In March 2025, Alcon ( ALC ) agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.

Alcon Terminates LENSAR Merger

Alcon ( ALC ) announced that it has agreed to terminate the merger agreement with LENSAR ( LNSR ) due to prolonged regulatory reviews that rendered the transaction unattractive.

The CEO of Alcon ( ALC ), David Endicott, emphasized that the acquisition would have significantly enhanced innovation in cataract surgery but cited the Federal Trade Commission’s opposition as a major factor in their decision.

“Alcon continues to believe that the acquisition of LENSAR ( LNSR ) would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission’s opposition.

Prior M&A Fallout

In January, STAAR Surgical Company ( STAA ) did not receive the necessary stockholder votes to approve the merger agreement with Alcon ( ALC ) at the Special Meeting of Stockholders.

Broadwood Partners, which owns a 30.2% stake in STAAR, opposed the proposed sale.

LNSR Technical Analysis” -32.5% vs 20-Day SMA

Currently, LENSAR ( LNSR ) is trading 32.5% below its 20-day simple moving average (SMA) and 34.8% below its 100-day SMA, demonstrating significant weakness.

Shares have decreased 34.15% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 30.83, which is considered neutral territory, while the MACD shows a value of -0.3091, below its signal line at -0.1204, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $9.00

Key Support: $7.00

LENSAR Momentum Score 9.51: Benzinga Edge

Below is the Benzinga Edge scorecard for LENSAR ( LNSR ), highlighting its strengths and weaknesses compared to the broader market:

Momentum: 9.51 — Stock is underperforming the broader market.

The Verdict: LENSAR’s Benzinga Edge signal reveals a weak profile, particularly in momentum, indicating challenges ahead as the company navigates its current market landscape.

LNSR Price Action: Lensar ( LNSR ) shares were down 25.44% at $7.65 during premarket trading on Tuesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Image via Shutterstock